Phase I clinical trial - Hématologie Lymphome non Hodgkinien
PRT2527-02
Hématologie Lymphome non Hodgkinien
Ouvert depuis le: 07.27.2024
Site: Saint-Cloud
Public cible
Adulte
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies.
Description de l'essai
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib.
Liens utiles